Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TVTX
TVTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TVTX News
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
15h ago
Fool
Director Roy D. Baynes Sells Shares of Travere Therapeutics
15h ago
NASDAQ.COM
Travere Therapeutics Prices $475M Convertible Notes Offering
3d ago
seekingalpha
Travere Therapeutics Prices $475 Million Convertible Notes Offering
4d ago
Newsfilter
Analysis of XBI ETF Trading Dynamics
4d ago
NASDAQ.COM
Travere Therapeutics Plans $400 Million Convertible Notes Offering
5d ago
seekingalpha
Travere Therapeutics Plans $400 Million Convertible Notes Offering
5d ago
Yahoo Finance
Travere Therapeutics Reports Q1 Profit Exceeding Estimates
5d ago
Newsfilter
Travere Therapeutics Director Sells Shares Amid FDA Approval
Apr 20 2026
Fool
Travere Therapeutics Secures FDA Approval for Filspari
Apr 20 2026
Yahoo Finance
US Stocks Surge as Oil Prices Plunge Amid Ceasefire Talks
Apr 15 2026
NASDAQ.COM
Travere Therapeutics Grants Equity Inducements to New Employees
Apr 14 2026
Newsfilter
US Stocks Rally as Oil Prices Plunge
Apr 14 2026
NASDAQ.COM
US Stocks Rise on Hopes of Iran Ceasefire Negotiations
Apr 14 2026
NASDAQ.COM
FDA Approves Filspari for Rare Kidney Disorder Treatment
Apr 14 2026
stocktwits
FDA Approves Travere and Ligand's Joint Kidney Disease Therapy Expansion
Apr 14 2026
seekingalpha
Show More News
